Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

The role of angiogenesis in tumor growth.

J Folkman · PubMed · 1992 · 1.3K citations

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 870 citations · Full text

Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein

Subbiah Pugazhenthi, Albina Nesterova, Carol L. Sable et al. · Journal of Biological Chemistry · 2000 · 791 citations · Full text

Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria

Hong‐Gang Wang, Ulf R. Rapp, John C. Reed · Cell · 1996 · 779 citations · Full text

Mitochondrial Function, Protein Kinase Raf-1, Medicine +2